Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Full article:

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following organizations have resources related to breast cancer. 

The National Comprehensive Cancer Network (NCCN) brings together national expert panels that create guidelines for cancer treatment. NCCN guidelines include recommendations for bone-protecting drugs during the treatment of early-stage, HR-positive breast cancer:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.